CN113730560A - 一种明眸亮采舒缓喷雾洗眼液及其制备方法 - Google Patents
一种明眸亮采舒缓喷雾洗眼液及其制备方法 Download PDFInfo
- Publication number
- CN113730560A CN113730560A CN202110899673.5A CN202110899673A CN113730560A CN 113730560 A CN113730560 A CN 113730560A CN 202110899673 A CN202110899673 A CN 202110899673A CN 113730560 A CN113730560 A CN 113730560A
- Authority
- CN
- China
- Prior art keywords
- eye
- eyes
- soothing
- extract
- brightening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001508 eye Anatomy 0.000 title claims abstract description 91
- 238000005406 washing Methods 0.000 title claims abstract description 11
- 238000005282 brightening Methods 0.000 title claims abstract description 10
- 239000007788 liquid Substances 0.000 title claims abstract description 10
- 241000167686 Reichardia Species 0.000 title claims abstract description 4
- 238000002360 preparation method Methods 0.000 title description 5
- 238000005507 spraying Methods 0.000 title description 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 28
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000007921 spray Substances 0.000 claims abstract description 16
- 229940088598 enzyme Drugs 0.000 claims abstract description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 14
- 102000004190 Enzymes Human genes 0.000 claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 claims abstract description 14
- 229960000458 allantoin Drugs 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000419 plant extract Substances 0.000 claims abstract description 11
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 10
- 229960005375 lutein Drugs 0.000 claims abstract description 10
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 10
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- 235000012680 lutein Nutrition 0.000 claims abstract description 7
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 7
- 239000001656 lutein Substances 0.000 claims abstract description 7
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 6
- SAVLIIGUQOSOEP-UHFFFAOYSA-N N-octanoylglycine Chemical compound CCCCCCCC(=O)NCC(O)=O SAVLIIGUQOSOEP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004310 lactic acid Substances 0.000 claims abstract description 6
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229940059958 centella asiatica extract Drugs 0.000 claims description 5
- 229940067866 dandelion extract Drugs 0.000 claims description 5
- 235000020691 dandelion extract Nutrition 0.000 claims description 5
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 5
- 102000016938 Catalase Human genes 0.000 claims description 4
- 108010053835 Catalase Proteins 0.000 claims description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 4
- 102000016943 Muramidase Human genes 0.000 claims description 4
- 108010014251 Muramidase Proteins 0.000 claims description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- 229960000274 lysozyme Drugs 0.000 claims description 4
- 239000004325 lysozyme Substances 0.000 claims description 4
- 235000010335 lysozyme Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 235000014104 aloe vera supplement Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 235000008210 xanthophylls Nutrition 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 125000004492 methyl ester group Chemical group 0.000 claims description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims 3
- 108010059892 Cellulase Proteins 0.000 claims 1
- 229940106157 cellulase Drugs 0.000 claims 1
- 230000004438 eyesight Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 208000030533 eye disease Diseases 0.000 abstract description 9
- 208000003464 asthenopia Diseases 0.000 abstract description 8
- 230000004089 microcirculation Effects 0.000 abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 abstract description 5
- 230000004044 response Effects 0.000 abstract description 4
- 235000002673 Dioscorea communis Nutrition 0.000 abstract description 3
- 241000544230 Dioscorea communis Species 0.000 abstract description 3
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 208000035753 Periorbital contusion Diseases 0.000 abstract description 3
- 238000006356 dehydrogenation reaction Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000004410 intraocular pressure Effects 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 29
- 239000000523 sample Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 208000002177 Cataract Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000001491 myopia Diseases 0.000 description 3
- 230000004379 myopia Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- -1 celloprotease Proteins 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 201000004573 corneal ectasia Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002899 effect on cataract Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01009—Glutathione peroxidase (1.11.1.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于日化领域。一种明眸亮采舒缓喷雾洗眼液,包括以下组分:尿囊素、丁二醇、透明质酸钠、复合生物酶、叶黄素、牛磺酸、植物提取物、乳酸、1,2‑己二醇、辛酰甘氨酸以及余量的水。本发明洗眼液利用囊泡运转理论和脱氢给氧技术可为眼部高效注入能量,提高眼部代谢能力,去除黑眼圈,消除水肿,紧致眼周,淡化细纹,快速分解清理眼部垃圾,即刻明亮双眼清晰视界,疏通眼部微循环,降低眼压,缓解眼部疲劳干涩,可有效预防和缓解多种常见的眼部疾病。使用方便,绿色安全,见效快,效果好。
Description
技术领域
本发明属于日化领域,具体涉及一种明眸亮采舒缓喷雾洗眼液及其制备方法。
背景技术
随着电子产品的普及,用眼过度,眼疲劳引起的眼部问题日益严重,但现有的眼部护理产品均不能快速高效的解决眼部问题,眼药水、眼贴膜等护眼产品,使用不便,见效慢,疗效差。因此,需要一种绿色安全,使用方便,针对眼部常见问题见效快、效果好的眼部护理产品。
发明内容
本发明所要解决的技术问题是提供一种明眸亮采舒缓喷雾洗眼液,该洗眼液利用囊泡运转理论和脱氢给氧技术可为眼部高效注入能量,提高眼部代谢能力,去除黑眼圈,消除水肿,紧致眼周,淡化细纹,快速分解清理眼部垃圾,即刻明亮双眼清晰视界,疏通眼部微循环,降低眼压,缓解眼部疲劳干涩,可有效预防和缓解多种常见的眼部疾病。使用方便,绿色安全,见效快,效果好。
本发明的技术方案如下:
一种明眸亮采舒缓喷雾洗眼液,包括以下按质量百分比计算的组分:尿囊素0.6-0.8%、丁二醇0.5-2%、透明质酸钠0.001-0.05%、复合生物酶0.01-0.2%、叶黄素0.01-0.02%、牛磺酸0.01-0.4%、植物提取物0.01-1.5%、乳酸0.01-0.6%、1,2-己二醇0.1-0.6%、辛酰甘氨酸0.1-0.6%以及余量的水。
A.生物复合酶
生物复合酶由多种酶组合而成,可实现多种酶的催化功效:抑菌消炎,清除自由基,抗衰老,修复肌肤和粘膜屏障。通过其接触上皮细胞,利用细胞自身的代谢物H2O,脱氢集氧,能够使细胞的含氧量迅速提升,并能够激活沉睡和亚休眠状态的细胞,促进细胞更新和组织代谢,促进细胞进行囊泡转运,当皮肤的微循环打通后,皮肤清除自由基和运输养料的通道更加通畅,根本解决肌肤的主动吸收问题,当皮肤的微循环打通后可促进上皮细胞得到修复增生,解决因细胞缺水缺氧造成的一系列皮肤问题。
B.尿囊素
尿囊素具有避光、杀菌防腐、止痛、抗氧化、保护组织的作用,能使皮肤保持水分、滋润和柔软,具有促进细胞生长、加快伤口愈合、软化角质蛋白等生理功能,加速细胞增殖分化,迅速形成表皮层,实现修复眼周肌肤、诱导新生、细腻嫩肤的效果。但尿囊素水溶性差,于一般的护肤品中添加量仅为0.3%,超过该剂量就会析出,水剂产品会呈现出针状凝结物,结晶等。申请人经大量实验证明了:低浓度的尿囊素对肌肤的护理和修复来说是远远不够的,因而限制了尿囊素在护肤品和药品中的应用。实验证明在护肤品中尿囊素添加量达0.6%及以上,其优异的护肤新能才能显现。本发明尿囊素的添加量0.6-0.8%,在分子上接入易溶于水的结构相似物,从而大大地改善了尿囊素的水溶性,可清除外层角质,疏通毛囊,促进微循环,提高活性成分的透皮吸收效率,改善和均匀肤色,淡化黑眼圈;促进细胞组织生长,加快伤口愈合,除皱抗皱,紧实眼周;具有优异的抗过敏作用,增强肌肤免疫力,帮助眼部抵御环境刺激,舒缓眼疲劳,预防眼部疾病;能够长效补水保湿,保持眼部肌肤湿润,避免眼睛干涩。
C.叶黄素
叶黄素作为一种光合色素,是视网膜的最重要的营养成分,也是构成视网膜黄斑区的最主要的必要成分,太阳光中的紫外光线和蓝光进入眼睛会产生大量自由基,紫外光通常能被眼角膜和晶状体过滤,蓝光可穿透眼球直达视网膜和黄斑,黄斑区中叶黄素能过滤蓝光,避免蓝光对眼睛造成伤害,但黄斑区的脂肪外层易受太阳光的氧化伤害,极易导致黄斑区退化,从而引发白内障等眼部疾病。叶黄素作为抗氧化剂,其具有良好抗氧化作用,可在光损伤中起光保护和营养视网膜感光细胞的作用,防止其凋亡,从而保护视力,延缓眼睛的老化和防治眼部病变。有效促进视网膜细胞中视紫质的再生,预防重度近视及视网膜剥离,并可增进视力,保护视力,缓解如视物模糊、眼干涩、眼胀、眼痛、畏光等视疲劳症状,提高黄斑色素密度,保护黄斑,促进黄斑发育,预防黄斑变性及视网膜色素变性,减少玻璃膜疣的产生,预防老年性黄斑变性的发生。
D.牛磺酸
牛磺酸又称β-氨基乙磺酸,是一种含硫的非蛋白氨基酸,牛磺酸是视网膜、玻璃体、晶状体、角膜、虹膜和睫状体中最丰富的氨基酸,可保护视网膜,牛磺酸具有调节晶体渗透压和抗氧化作用,可抑制晶体中的蛋白质氧化,从而避免了白内障的发生。牛磺酸具有抗菌消炎、舒缓镇静的作用,可有效缓解视疲劳,有助于视觉功能的正常维持,保护视力。
进一步的,所述复合生物酶包括纤维蛋白酶、溶菌酶、超氧化物歧化酶、谷胱甘肽过氧化物酶、过氧化氢酶中的至少一种。
进一步的,所述复合生物酶为质量比1:1-3:1-3:1-3:1-3的纤维蛋白酶、溶菌酶、超氧化物歧化酶、谷胱甘肽过氧化物酶和过氧化氢酶。
进一步的,所述植物提取物包括蒲公英提取物、积雪草提取物、芦荟提取物中的至少一种。
蒲公英提取物可抑菌消炎,促进细胞生长,清除自由基,抗氧化,延缓衰老,紧致眼周,除皱祛皱,具有较强的角膜渗透力,保护视网膜,改善视力,缓解眼部常见疾病。积雪草提取物可抗菌消炎,清除自由基,抗氧化,刺激成纤维细胞增殖分化,可显著提高胶原蛋白和细胞层纤连蛋白含量,修复肌肤自身屏障功能,提高肌肤含水量,恢复眼部肌肤弹性,延缓肌肤衰老。芦荟提取物可促进纤维蛋白的增长和胶原蛋白的合成,抑制弹性蛋白,清除自由基,抗菌消炎,补水保湿,恢复眼部肌肤弹性,缓解眼部干涩。
进一步的,所述植物提取物为蒲公英提取物0.02-1%、积雪草提取物0.01-0.6%和芦荟提取物0.01-0.6%。
进一步的,还包括防腐剂0.001-0.01%。
进一步的,所述防腐剂为甲酯。
一种所述的明眸亮采舒缓喷雾洗眼液的制备方法,包括以下步骤:将水、丁二醇、尿囊素、透明质酸钠、复合生物酶混合,加热至85-95℃搅拌20-30min;降温至39-45℃,加入1,2-己二醇和辛酰甘氨酸的混合物,搅拌10-20min;降温至37℃以下,加入叶黄素、牛磺酸、植物提取物和乳酸,搅拌10-20min即可。
本发明具有如下有益效果:
本发明通过多种植物提取物和活性成分复配,可深入滋养眼部肌肤细胞,高效补充胶原蛋白和弹性纤维,可使眼部肌肤充满弹性,紧实眼周肌肤,抗皱祛皱;高效分解眼部垃圾,疏通眼部细胞微循环,加速新陈代谢,缓解眼部疲劳干涩,明亮双眼,清晰视界,预防近视,保护视力,补水滋润、修复、消炎止痒、愈合伤口、分解游离基、促进新陈代谢,可有效预防和缓解视疲劳、近视弱视、干涩瘙痒、眼部酸胀、红血丝、角膜炎、飞蚊症、老花眼、迎风流泪等眼部疾病。
具体实施方式
下面结合实施例对本发明进行详细的说明,实施例仅是本发明的优选实施方式,不是对本发明的限定。
实施例
下表为本发明明眸亮采舒缓喷雾洗眼液3个实施例的配方表(单位:%):
一种所述的明眸亮采舒缓喷雾洗眼液的制备方法,包括以下步骤:将水、丁二醇、尿囊素、透明质酸钠、复合生物酶混合,加热至85℃搅拌20min;降温至39℃,加入1,2-己二醇和辛酰甘氨酸的混合物,搅拌10min;降温至37℃以下,加入叶黄素、牛磺酸、植物提取物和乳酸,搅拌10min即可。
对比例
下表为本发明明眸亮采舒缓喷雾洗眼液3个对比例的配方表(单位:%),制备方法为本领域常规的混合搅拌:
测试本发明明眸亮采舒缓喷雾洗眼液3个实施例和3个对比例的性能:
一、缓解红血丝和角膜扩张测试
将浓度为3M的苯酚水溶液灭菌后,取10μL,施用于眼部健康、无红血丝的2月龄大鼠双眼角膜中心,施用周期为一粥,每日施用一次,选取30只双眼出现血管和角膜扩张现象的大鼠,分为甲、乙、丙三组,每组10只,甲组左右眼分别施用实施例1和对比例1,乙组左右眼分别施用实施例2和对比例2,丙组左右眼分别施用实施例3和对比例3,用量为1ml,施用一滴样品吸收后再施用下一滴,每次施药时长10-30min,受试周期为7天,观察统计7天后眼部红血丝和圆锥形角膜痊愈、有效、无效的大鼠数量,测试结果见下表:
可见,本发明可有效缓解眼部红血丝和角膜扩张现象,见效快,疗程短。
二、治疗白内障测试
选取60名年龄60岁以上、患病程度接近的白内障患者,分为6组,每组10人,早晚施用5ml样品洗眼,洗眼液与患病部位接触时长≥60s,测试周期为20天,观察20天后患者晶珠浑浊减少、视力恢复情况,统计痊愈、显效、有效、无效人数,测试结果见下表:
可见,本发明对白内障的治疗效果好,见效快,疗程短。
三、改善眼周肌肤测试
1、测试项目:皮肤黑色素含量、水分含量、皮肤弹性。
2、测试仪器:CKMPA580皮肤测试仪、Mexameter皮肤黑色素测试探头、Corneometer水分测试探头、Cutometer皮肤弹性测试探头。
3、受试对象:筛选眼部有黑眼圈、眼袋浮肿、无眼疾的合格志愿者,选择眼周作为测试部位。实施例1-3、对比例1-3每组各20名受试者。
4、测试周期:测试周期为15天,在使用样品前1天和使用后第15天使用仪器测试各项指标。在使用后的测试中,志愿者在测试当天不能涂抹样品,需要测试完成后再使用样品。
5、样品使用:测试前1周为洗脱期,此期间受试者使用不含任何活性物的基础保湿水和保湿乳。在测试期间不能使用其他美白产品。受试者连续15天使用样品,每天早晨、晚上睡前洗脸后在眼周涂膜样品,涂抹量约为0.5ml。测试黑色素含量以脸部作为自身对照用。
6、测试过程:使用前数据采集:测试前,在温度为24±1℃、湿度为55±5%RH的恒温恒湿室内静坐20分钟。用Mexameter皮肤黑色素测试探头、Corneometer水分测试探头、Cutometer皮肤弹性测试探头在测试部位进行使用前数据的采集。对各测试部位的各测试点循环测试4次,取平均值作为对应部位的使用前数据。
7、使用后第15天的数据采集,步骤同使用前数据采集。
8、测试结果见下表:
(1):
可见,本发明洗眼液可显著的降低皮肤黑色素含量,增加皮肤水分含量,提高肌肤弹性,有效去除黑眼圈,紧致眼周肌肤。
本发明洗眼液利用囊泡运转理论和脱氢给氧技术可为眼部高效注入能量,提高眼部代谢能力,去除黑眼圈,消除水肿,紧致眼周,淡化细纹,快速分解清理眼部垃圾,即刻明亮双眼清晰视界,疏通眼部微循环,降低眼压,缓解眼部疲劳干涩,可有效预防和缓解多种常见的眼部疾病。使用方便,绿色安全,见效快,效果好。
Claims (8)
1.一种明眸亮采舒缓喷雾洗眼液,其特征在于,包括以下按质量百分比计算的组分:尿囊素0.6-0.8%、丁二醇0.5-2%、透明质酸钠0.001-0.05%、复合生物酶0.01-0.2%、叶黄素0.01-0.02%、牛磺酸0.01-0.4%、植物提取物0.01-1.5%、乳酸0.01-0.6%、1,2-己二醇0.1-0.6%、辛酰甘氨酸0.1-0.6%以及余量的水。
2.根据权利要求1所述的明眸亮采舒缓喷雾洗眼液,其特征在于,所述复合生物酶包括纤维蛋白酶、溶菌酶、超氧化物歧化酶、谷胱甘肽过氧化物酶、过氧化氢酶中的至少一种。
3.根据权利要求1所述的明眸亮采舒缓喷雾洗眼液,其特征在于,所述复合生物酶为质量比1:1-3:1-3:1-3:1-3的纤维蛋白酶、溶菌酶、超氧化物歧化酶、谷胱甘肽过氧化物酶和过氧化氢酶。
4.根据权利要求1所述的明眸亮采舒缓喷雾洗眼液,其特征在于,所述植物提取物包括蒲公英提取物、积雪草提取物、芦荟提取物中的至少一种。
5.根据权利要求1所述的明眸亮采舒缓喷雾洗眼液,其特征在于,所述植物提取物为蒲公英提取物0.02-1%、积雪草提取物0.01-0.6%和芦荟提取物0.01-0.6%。
6.根据权利要求1所述的明眸亮采舒缓喷雾洗眼液,其特征在于,还包括防腐剂0.001-0.01%。
7.根据权利要求6所述的明眸亮采舒缓喷雾洗眼液,其特征在于,所述防腐剂为甲酯。
8.一种权利要求1-7任一项所述的明眸亮采舒缓喷雾洗眼液的制备方法,其特征在于,包括以下步骤:将水、丁二醇、尿囊素、透明质酸钠、复合生物酶混合,加热至85-95℃搅拌20-30min;降温至39-45℃,加入1,2-己二醇和辛酰甘氨酸的混合物,搅拌10-20min;降温至37℃以下,加入叶黄素、牛磺酸、植物提取物和乳酸,搅拌10-20min即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110899673.5A CN113730560A (zh) | 2021-08-06 | 2021-08-06 | 一种明眸亮采舒缓喷雾洗眼液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110899673.5A CN113730560A (zh) | 2021-08-06 | 2021-08-06 | 一种明眸亮采舒缓喷雾洗眼液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113730560A true CN113730560A (zh) | 2021-12-03 |
Family
ID=78730293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110899673.5A Pending CN113730560A (zh) | 2021-08-06 | 2021-08-06 | 一种明眸亮采舒缓喷雾洗眼液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113730560A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726151A (zh) * | 2023-03-13 | 2023-09-12 | 河北纳科生物科技有限公司 | 一种用于角膜损伤修复的日抛型滴眼液及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
CN101716214A (zh) * | 2009-12-23 | 2010-06-02 | 四川大学 | 含有蒲公英提取物的药物组合物及其新用途和制备方法 |
US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
CN102178925A (zh) * | 2011-04-25 | 2011-09-14 | 崔晓廷 | 新型视力保护剂叶黄素眼用制剂 |
WO2017130130A1 (en) * | 2016-01-28 | 2017-08-03 | Roberto Pinelli | Nutritional supplement for maintaining the state of health of the eye |
RU2660366C1 (ru) * | 2017-03-31 | 2018-07-05 | Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" | Средство для профилактики и лечения глазных заболеваний, таких как заболевания сетчатки, глаукома и катаракта. |
CN110123695A (zh) * | 2019-06-03 | 2019-08-16 | 惠州学院 | 一种细胞能量修复组合物 |
CN110787082A (zh) * | 2019-09-29 | 2020-02-14 | 广州达达眼健康管理有限公司 | 一种眼部细胞修复组合物及包含该组合物的眼部护理品 |
CN112999124A (zh) * | 2021-03-04 | 2021-06-22 | 同方药业集团有限公司 | 一种护眼喷雾及其制备方法 |
-
2021
- 2021-08-06 CN CN202110899673.5A patent/CN113730560A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
CN101716214A (zh) * | 2009-12-23 | 2010-06-02 | 四川大学 | 含有蒲公英提取物的药物组合物及其新用途和制备方法 |
US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
CN102178925A (zh) * | 2011-04-25 | 2011-09-14 | 崔晓廷 | 新型视力保护剂叶黄素眼用制剂 |
WO2017130130A1 (en) * | 2016-01-28 | 2017-08-03 | Roberto Pinelli | Nutritional supplement for maintaining the state of health of the eye |
RU2660366C1 (ru) * | 2017-03-31 | 2018-07-05 | Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" | Средство для профилактики и лечения глазных заболеваний, таких как заболевания сетчатки, глаукома и катаракта. |
CN110123695A (zh) * | 2019-06-03 | 2019-08-16 | 惠州学院 | 一种细胞能量修复组合物 |
CN110787082A (zh) * | 2019-09-29 | 2020-02-14 | 广州达达眼健康管理有限公司 | 一种眼部细胞修复组合物及包含该组合物的眼部护理品 |
CN112999124A (zh) * | 2021-03-04 | 2021-06-22 | 同方药业集团有限公司 | 一种护眼喷雾及其制备方法 |
Non-Patent Citations (2)
Title |
---|
李佳圆: "常见慢性非传染性疾病的防治 第2版", 30 April 2021, 四川大学出版社, pages: 168 * |
高兴华;刘小杰;欧凯;: "视疲劳与营养干预", 饮料工业, no. 06, 28 June 2010 (2010-06-28) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726151A (zh) * | 2023-03-13 | 2023-09-12 | 河北纳科生物科技有限公司 | 一种用于角膜损伤修复的日抛型滴眼液及其制备方法 |
CN116726151B (zh) * | 2023-03-13 | 2024-04-09 | 河北纳科生物科技有限公司 | 一种用于角膜损伤修复的日抛型滴眼液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102935055B (zh) | 一种纯露保湿面膜 | |
CN113304310A (zh) | 一种具有修复功能的医用湿性敷料及其制备方法 | |
KR20200139970A (ko) | 탈모방지 및 발모촉진용 샴푸 및 그 제조방법 | |
CN100453086C (zh) | 一种冰珍去翳眼用凝胶制剂及其制备方法 | |
CN111514055A (zh) | 一种具有抗炎修复功效的化妆品用多肽组合物颗粒剂 | |
CN113730560A (zh) | 一种明眸亮采舒缓喷雾洗眼液及其制备方法 | |
CN114288221A (zh) | 一种有生发作用的含多肽和植物提取液的精华液的制备方法及其应用 | |
CN111067820A (zh) | 一种植物修护精华乳及其制备方法 | |
CN111773114A (zh) | 一种负离子水晶眼贴膜 | |
CN111658592A (zh) | 一种眼部精华液及其制备方法 | |
CN107519118A (zh) | 一种蛇胆眼膜及其制备方法 | |
CN110859758A (zh) | 一种美白抗衰老修复型医用冷敷贴及其制备方法 | |
CN113069373A (zh) | 一种干眼眼霜、制备方法及应用 | |
CN113230154B (zh) | 一种具有抗敏舒缓消炎作用的组合物及其制备方法和用途 | |
CN107007511A (zh) | 一种具有治愈激素脸功效的化妆品组合物及其制备方法和应用 | |
CN113925828A (zh) | 一种龙脑洗眼液 | |
CN109453104B (zh) | 淡斑爽肤精华液及其制备工艺 | |
CN113332175A (zh) | 医用湿性修复贴 | |
CN113274337A (zh) | 一种医用皮肤修复护理膜及其制备方法 | |
CN105902686A (zh) | 一种含有纳米碳晶的原位凝胶眼药水及其制备方法 | |
CN108078906B (zh) | 一种烫染发用茶油发膜及其制作方法和应用 | |
CN114099551B (zh) | 缓解视疲劳润眼组合物 | |
CN115364028B (zh) | 一种生物肽赋活修护面膜液及其制备方法 | |
KR20090003828A (ko) | 탈모방지 및 발모 조성물을 함유하는 헤어토닉 | |
CN113181087B (zh) | 祛细纹组合物及其应用和眼部护理膜片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |